Patents Assigned to Onyx Pharmaceuticals, Inc.
-
Patent number: 6225060Abstract: The present invention provides novel recombinant baculovirus expression systems for expressing foreign genetic material in a host cell. Such expression systems are readily adapted to an automated method for expression foreign genetic material in a high throughput manner. In other aspects, the present invention features a novel automated method for determining the function of foreign genetic material by transfecting the same into a host by way of the recombinant baculovirus expression systems according to the present invention.Type: GrantFiled: March 4, 1999Date of Patent: May 1, 2001Assignee: Onyx Pharmaceuticals, Inc.Inventors: Robin Clark, Anthony Davies
-
Nucleotide sequences that encode phosphatidylinositol-3' kinase associated proteins and uses thereof
Patent number: 6133419Abstract: Identification, characterization and expression of nucleotides that encode phosphatidylinositol-3' kinase associated protein(s) that bind to the intermediate SH2 domain on the regulatory subunit of PI3K, p85, by the associated protein(s) C-terminal amino acids, and that exhibit a bromodomain are described, as well as methods of using such proteins for medical applications, including diagnosis and treatment cell growth disorders.Type: GrantFiled: October 1, 1997Date of Patent: October 17, 2000Assignee: Onyx Pharmaceuticals, Inc.Inventor: Sylvia Braselmann -
Patent number: 6133243Abstract: Methods and compositions for treating cancer consisting of viral DNA in association with liposomal material, the viral DNA substantially incapable of encoding a functional viral oncoprotein capable of binding to a functional tumor suppressor gene product in a neoplastic cell, and the viral DNA capable of replicating and forming infectious virus in neoplastic cells thereby killing the neoplastic cells and substantially incapable of replicating and forming infectious virus in non-neoplastic cells that have the tumor suppressor protein.Type: GrantFiled: February 22, 1996Date of Patent: October 17, 2000Assignee: Onyx Pharmaceuticals, Inc.Inventor: David Kirn
-
Patent number: 6080578Abstract: Methods and compositions for treating neoplastic conditions by viral-based therapy are provided. Mutant virus lacking viral proteins which bind and/or inactivate p53 or RB are administered to a patient having a neoplasm which comprises cells lacking p53 and/or RB function. The mutant virus is able to substantially produce a replication phenotype in neoplastic cells but is substantially unable to produce a replication phenotype in non-replicating, non-neoplastic cells having essentially normal p53 and/or RB function. The preferential generation of replication phenotype in neoplastic cells results in a preferential killing of the neoplastic cells, either directly or by expression of a cytotoxic gene in cells expressing a viral replication phenotype.Type: GrantFiled: December 8, 1997Date of Patent: June 27, 2000Assignee: Onyx Pharmaceuticals, Inc.Inventors: James R. Bischoff, Julie Nye, Lelia Ng, Sharon Horn, Angelica Williams, David Kirn
-
Patent number: 6048706Abstract: A novel human serine protein kinase, human p21-protein activated serine kinase p65 protein, referred to as hPAK65, and methods for its preparation and use are provided. Nucleic acids encoding hPAK65 and methods for their use in preparing hPAK65 as well as in preparing and identifying hPAK65 analogs are provided. Methods provided for the use of hPAK65 protein and its protein fragments, such as those that retain at least one hPAK65 activity, that include screening libraries of agents for candidates that modulate hPAK65 activity. Methods are provided to identify agents that modulate the interaction of hPAK65 with rho-like p21 GTPases, particularly rac1 and CDC42Hs binding to hPAK65 and subsequent activation of hPAK65 serine protein kinase activity, that modulate hPAK65 serine protein kinase activity, and that modulate hPAK65 effect on p21 protein GTPase activity.Type: GrantFiled: July 1, 1998Date of Patent: April 11, 2000Assignee: Onyx Pharmaceuticals, Inc.Inventors: Arie Abo, George A. Martin
-
Patent number: 6017763Abstract: The present invention relates to the discovery, identification and characterization of nucleotides that encode the G protein regulated phosphatidylinositol-3' kinase, a heterodimeric enzyme which produces the intracellular messenger phosphatidylinositol (3,4,5)-triphosphate in response to activation of trimeric G protein-linked receptors. This novel protein, comprised of a catalytic subunit, p120, and a regulatory subunit, p101, is found in cells of hematopoietic origin and is involved in immune system responses which cause inflammation. The presence of p101 subunit is largely responsible for the dramatic stimulation of kinase activity in the presence of activated trimeric G proteins.Type: GrantFiled: January 4, 1999Date of Patent: January 25, 2000Assignees: Onyx Pharmaceuticals, Inc., The Babraham InstituteInventors: Len Stephens, Phillip Thomas Hawkins, Sylvia Braselmann
-
Patent number: 6013464Abstract: A novel human serine protein kinase, human p21-protein activated serine kinase p65 protein, referred to as hPAK65, and methods for its preparation and use are provided. Nucleic acids encoding hPAK65 and methods for their use in preparing hPAK65 as well as in preparing and identifying hPAK65 analogs are provided. Methods provided for the use of hPAK65 protein and its protein fragments, such as those that retain at least one hPAK65 activity, that include screening libraries of agents for candidates that modulate hPAK65 activity. Methods are provided to identify agents that modulate the interaction of hPAK65 with rho-like p21 GTPases, particularly rac 1 and CDC42Hs binding to hPAK65 and subsequent activation of hPAK65 serine protein kinase activity, that modulate hPAK65 serine protein kinase activity, and that modulate hPAK65 effect on p21 protein GTPase activity.Type: GrantFiled: August 22, 1997Date of Patent: January 11, 2000Assignee: Onyx Pharmaceuticals, Inc.Inventors: Arie Abo, George A. Martin
-
Patent number: 5948643Abstract: Compositions of matter consisting of a family of related nucleotide sequences that encode proteins, termed BRCA1 Modulator Proteins, that bind to the tumor suppressor gene product BRCA1, and methods of using the nucleotide sequences and the proteins encoded thereby, to diagnose and/or treat disease where the BRCA1 Modulator Proteins have an apparent molecular weight of 45-97 kdaltons and are characterized by having at least one leucine zipper domain, and optionally a zinc finger domain.Type: GrantFiled: August 13, 1997Date of Patent: September 7, 1999Assignee: Onyx Pharmaceuticals, Inc.Inventors: Bonnee Rubinfeld, Paul G. Polakis, Carol Lingenfelter, Terilyn T. Vuong
-
Patent number: 5876711Abstract: Methods and compositions for determining the tumor suppressor status of cells are described, preferably as pertaining to the p53 status of tumor cells, and preferably in vivo using a recombinant construct consisting of a first polynucleotide sequence that encodes a reporter molecule and a second p53 binding polynucleotide sequence that is operably linked to the first polynucleotide sequence such that binding of p53 to the second polynucleotide sequence causes the expression of the reporter molecule which can be detected or quantified.Type: GrantFiled: May 31, 1996Date of Patent: March 2, 1999Assignee: Onyx Pharmaceuticals, Inc.Inventor: Ali Fattaey
-
Patent number: 5856181Abstract: Methods and compositions for treating neoplastic conditions by viral-based therapy are provided. Mutant virus lacking viral proteins which bind and/or inactivate p53 or RB are administered to a patient having a neoplasm which comprises cells lacking p53 and/or RB function. The mutant virus is able to substantially produce a replication phenotype in neoplastic cells but is substantially unable to produce a replication phenotype in non-replicating, non-neoplastic cells having essentially normal p53 and/or RB function. The preferential generation of replication phenotype in neoplastic cells results in a preferential killing of the neoplastic cells, either directly or by expression of a cytotoxic gene in cells expressing a viral replication phenotype.Type: GrantFiled: October 14, 1997Date of Patent: January 5, 1999Assignee: Onyx Pharmaceuticals, Inc.Inventor: Francis McCormick
-
Patent number: 5846945Abstract: Methods and compositions for treating neoplastic conditions by viral-based therapy are provided. Mutant virus lacking viral proteins which bind and/or inactivate p53 or RB are administered to a patient having a neoplasm which comprises cells lacking p53 and/or RB function. The mutant virus is able to substantially produce a replication phenotype in neoplastic cells but is substantially unable to produce a replication phenotype in non-replicating, non-neoplastic cells having essentially normal p53 and/or RB function. The preferential generation of replication phenotype in neoplastic cells results in a preferential killing of the neoplastic cells, either directly or by expression of a cytotoxic gene in cells expressing a viral replication phenotype.Type: GrantFiled: June 7, 1995Date of Patent: December 8, 1998Assignee: ONYX Pharmaceuticals, Inc.Inventor: Francis McCormick
-
Patent number: 5801029Abstract: Methods and compositions for treating neoplastic conditions by viral-based therapy are provided. Mutant virus lacking viral proteins which bind and/or inactivate p53 or RB are administered to a patient having a neoplasm which comprises cells lacking p53 and/or RB function. The mutant virus is able to substantially produce a replication phenotype in neoplastic cells but is substantially unable to produce a replication phenotype in non-replicating, non-neoplastic cells having essentially normal p53 and/or RB function. The preferential generation of replication phenotype in neoplastic cells results in a preferential killing of the neoplastic cells, either directly or by expression of a cytotoxic gene in cells expressing a viral replication phenotype.Type: GrantFiled: June 7, 1995Date of Patent: September 1, 1998Assignee: Onyx Pharmaceuticals, Inc.Inventor: Francis McCormick
-
Patent number: 5756669Abstract: The invention provides mammalian polypeptides which bind wild-type and/or mutant mamalian p53 proteins, polynucleotides encoding such polypeptides, screening assays for drug development employing such polypeptides and polynucleotides, immunological and other reagents for diagnostic, therapeutic, and research applications.Type: GrantFiled: March 2, 1995Date of Patent: May 26, 1998Assignee: Onyx Pharmaceuticals, Inc.Inventors: James R. Bischoff, Lelia Wu
-
Patent number: 5705342Abstract: The invention provides compositions and methods for screening for agents which are modulators of bcl-2 function and can modulate bcl-2-mediated apoptosis and/or modulate neoplastic and immune conditions dependent upon bcl-2 function. The invention also provides a composition comprising a substantially pure protein complex comprising a R-ras polypeptide and a bcl-2 polypeptide.Type: GrantFiled: June 7, 1995Date of Patent: January 6, 1998Assignee: Onyx Pharmaceuticals, Inc.Inventors: James R. Bischoff, Maria Jose Fernandez-Sarabia
-
Patent number: 5698428Abstract: A novel human serine protein kinase, human p21-protein activated serine kinase p65 protein, referred to as hPAK65, and methods for its preparation and use are provided. Nucleic acids encoding hPAK65 and methods for their use in preparing hPAK65 as well as in preparing and identifying hPAK65 analogs are provided. Methods provided for the use of hPAK65 protein and its protein fragments, such as those that retain at least one hPAK65 activity, that include screening libraries of agents for candidates that modulate hPAK65 activity. Methods are provided to identify agents that modulate the interaction of hPAK65 with rho-like p21 GTPases, particularly rac1 and CDC42Hs binding to hPAK65 and subsequent activation of hPAK65 serine protein kinase activity, that modulate hPAK65 serine protein kinase activity, and that modulate hPAK65 effect on p21 protein GTPase activity.Type: GrantFiled: January 10, 1997Date of Patent: December 16, 1997Assignee: Onyx Pharmaceuticals, Inc.Inventors: Arie Abo, George A. Martin
-
Patent number: 5698445Abstract: A novel human serine protein kinase, human p21-protein activated serine kinase p65 protein, referred to as hPAK65, and methods for its preparation and use are provided. Nucleic acids encoding hPAK65 and methods for their use in preparing hPAK65 as well as in preparing and identifying hPAK65 analogs are provided. Methods provided for the use of hPAK65 protein and its protein fragments, such as those that retain at least one hPAK65 activity, that include screening libraries of agents for candidates that modulate hPAK65 activity. Methods are provided to identify agents that modulate the interaction of hPAK65 with rho-like p21 GTPases, particularly rac1 and CDC42Hs binding to hPAK65 and subsequent activation of hPAK65 serine protein kinase activity, that modulate hPAK65 serine protein kinase activity, and that modulate hPAK65 effect on p21 protein GTPase activity.Type: GrantFiled: April 22, 1996Date of Patent: December 16, 1997Assignee: Onyx Pharmaceuticals, Inc.Inventors: Arie Abo, George A. Martin
-
Patent number: 5677178Abstract: Methods and compositions for treating neoplastic conditions by viral-based therapy are provided. Mutant virus lacking viral proteins which bind and/or inactivate p53 or RB are administered to a patient having a neoplasm which comprises cells lacking p53 and/or RB function. The mutant virus is able to substantially produce a replication phenotype in neoplastic cells but is substantially unable to produce a replication phenotype in non-replicating, non-neoplastic cells having essentially normal p53 and/or RB function. The preferential generation of replication phenotype in neoplastic cells results in a preferential killing of the neoplastic cells, either directly or by expression of a cytotoxic gene in cells expressing a viral replication phenotype.Type: GrantFiled: April 29, 1996Date of Patent: October 14, 1997Assignee: ONYX Pharmaceuticals, Inc.Inventor: Francis McCormick
-
Patent number: 5605825Abstract: A novel human serine protein kinase, human p21-protein activated serine kinase p65 protein, referred to as hPAK65, and methods for its preparation and use are provided. Nucleic acids encoding hPAK65 and methods for their use in preparing hPAK65 as well as in preparing and identifying hPAK65 analogs are provided. Methods provided for the use of hPAK65 protein and its protein fragments, such as those that retain at least one hPAK65 activity, that include screening libraries of agents for candidates that modulate hPAK65 activity. Methods are provided to identify agents that modulate the interaction of hPAK65 with rho-like p21 GTPases, particularly racl and CDC42Hs binding to hPAK65 and subsequent activation of hPAK65 serine protein kinase activity, that modulate hPAK65 serine protein kinase activity, and that modulate hPAK65 effect on p21 protein GTPase activity.Type: GrantFiled: June 7, 1995Date of Patent: February 25, 1997Assignee: Onyx Pharmaceuticals, Inc.Inventors: Arie Abo, George A. Martin
-
Patent number: 5597719Abstract: Intermolecular interactions between Raf-1 and human 14-3-3 proteins which regulate Raf activity are identified. Compositions and method for identifying novel drugs which modulate Raf activity in vivo are provided.Type: GrantFiled: July 14, 1994Date of Patent: January 28, 1997Assignee: Onyx Pharmaceuticals, Inc.Inventors: Ellen Freed, Rosamaria Ruggieri
-
Patent number: 5539085Abstract: The invention provides compositions and methods for screening for agents which are modulators of bcl-2 function and can modulate bcl-2-mediated apoptosis and/or modulate neoplastic and immune conditions dependent upon bcl-2 function. The invention also provides a composition comprising a substantially pure protein complex comprising a R-ras polypeptide and a bcl-2 polypeptide.Type: GrantFiled: August 20, 1993Date of Patent: July 23, 1996Assignee: Onyx Pharmaceuticals, Inc.Inventors: James R. Bischoff, Maria J. Fernandez-Sarabia